Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:12:01 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:NVO - NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1 - https://www.novonordisk-us.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVO - Z4.049.60·49.920.447.64+4.32510.036,780.21,673,904158,46946.37  47.74  45.8493.80  43.0819:59:54Jan 0515 min RT 2¢

Recent Trades - Last 10 of 158469
Time ETExPriceChangeVolume
19:59:54Z49.896.555
19:59:44Z49.946.603,000
19:59:44Z49.946.602,094
19:59:44Z49.946.6010
19:59:43Z49.916.57400
19:59:39Z49.946.60100
19:59:38Z49.91096.5709200
19:59:35Z49.916.5739
19:59:34Z49.926.58120
19:59:31Z49.90026.560265

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-05 08:00U:NVONews ReleaseNovo Nordisk's Wegovy(TM) pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
2025-12-16 12:00U:NVONews ReleaseFrom Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
2025-11-06 14:30U:NVONews ReleaseNovo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek(TM)
2025-08-15 17:30U:NVONews ReleaseWegovy(TM) approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
2025-06-26 11:09U:NVONews ReleaseNovo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy(TM) and prioritize patient safety
2025-06-23 08:03U:NVONews ReleaseNovo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
2025-05-22 08:00U:NVONews ReleaseNew Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy(TM) as federal ban on mass compounding of "semaglutide" takes effect
2025-03-24 08:00U:NVONews ReleaseNovo Nordisk expands Wegovy(TM) $499-per-month offering to additional cash-paying patients via the Wegovy(TM) savings offer
2025-03-05 08:00U:NVONews ReleaseNovo Nordisk introduces NovoCare(TM) Pharmacy, lowering cost of all doses of FDA-approved Wegovy(TM) (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
2025-02-18 18:21U:NVONews ReleaseINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO